Home > Boards > US Listed > Cannabis > Rising India, Inc (RSII)

$RSII Corporate Research Team/Website/Solid DD

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
LionsPride Member Profile
Followed By 74
Posts 3,771
Boards Moderated 0
Alias Born 06/29/16
160x600 placeholder
Rising Biosciences Expedites Growth/Expansion with In-House Chemist, Laboratory Analytical Equipment and Producer/Processor InvestorsHub NewsWire - 3/20/2018 11:45:21 AM
Emerging Growth CBD Company (HIPH) Major International Distribution Agreement InvestorsHub NewsWire - 3/15/2018 8:13:05 AM
RSII To Offer Cannophen to Patients in Ohio, Florida; Prepares for National Distribution of Scar Peptide Serum InvestorsHub NewsWire - 2/20/2018 9:45:00 AM
American Premium Water Corp. (OTC Pink: HIPH) Delivers Hydrogen Infused CBD Water InvestorsHub NewsWire - 1/29/2018 7:58:37 AM
Rising Biosciences, Inc. Develops Groundbreaking Oral THC/CBD Delivery Capsule Cannophen; Nears Completion on MMJ Laboratory in InvestorsHub NewsWire - 1/18/2018 9:30:00 AM
Rising Biosciences, Inc. Launches TSW! Topicals (This S#*!t Works!), Delivering Innovative Pain Relief to Market in Q4... InvestorsHub NewsWire - 9/29/2017 8:30:00 AM
MJAC 2017 Speaker Update - How venture capital and cryptocurrency are converging as the future of cannabis investing InvestorsHub NewsWire - 8/30/2017 10:29:33 PM
PotNetwork Holdings, Inc Confirmed for MJAC 2017 InvestorsHub NewsWire - 8/28/2017 10:43:55 AM
MJAC 2017 International Cannabis Conference - Discount Code InvestorsHub NewsWire - 8/25/2017 6:50:56 PM
Book your ticket now for InvestorsHubs International Cannabis Conference InvestorsHub NewsWire - 8/23/2017 12:50:25 PM
MJAC 2017 - Speaker Update - Investing In The U.S. Cannabis Market InvestorsHub NewsWire - 8/22/2017 1:27:13 AM
Rising Biosciences, Inc. Initiates Testing for FDA Approval of OTC Chronic Pain Relief Medications InvestorsHub NewsWire - 8/2/2017 12:28:19 PM
Friendable Inc. (OTC Pink: FDBL), Metrics Up, Growth Continues Reaches Number 1 Ranking in Canada InvestorsHub NewsWire - 3/23/2017 9:00:00 AM
LionsPride   Thursday, 04/27/17 12:38:36 PM
Re: None
Post # of 59824 
$RSII Corporate Research Team/Website/Solid DD

Dr. Gary Bernard - Medical License (Chief Medical Officer)

Richard Vallette - Medical Licenses (Director of Pharmacology)

Rising Biosciences, Inc. Launches Corporate Website, Announces Executive Research Team

Apr 27, 2017
OTC Disclosure & News Service


Rising Biosciences, Inc. Launches Corporate Website, Announces Executive Research Team

NEW YORK, NY--(Marketwired - Apr 27, 2017) - Rising India Inc. (OTC: RSII) is pleased to announce that Rising Biosciences, Inc., The Company's recently finalized merger entity, has officially launched its corporate website, detailing its mission statement, corporate objectives and newly appointed research executives.

Rising Biosciences, Inc. is a research & development company focusing on oral and topical cannabis and non-cannabis based pharmaceuticals with strict standards set forward by the pharmaceutical compounding industry. Operations will be helmed by a team of chemists, physicians, pharmacists and medical marijuana industry veterans for the development of products in a clinical lab environment with a focus on creating product that can be metabolized by the body more efficiently, and with delivery methods more acceptable than smoking, tinctures and oils available on the market today.

In addition to C-Level execs including previously announced execs CEO Robert Weber and Jim DiPrima, who will serve as CFO, the Rising Biosciences has also secured Arthur Hall as Chief Operating Officer. Hall, a seasoned executive in the medical marijuana industry, has extensive experience in laboratory environments in the states of Washington and Oregon, as well as a hands-on background in processing and production, particularly in development of new safe extraction methods, which have become industry standards today.

Rising Biosciences has assembled an impressive team of executives including its Chief Medical Officer, Gary C. Bernard, M.D. who also serves as President & CEO of Pointe Medical Services, Inc., Pointe Med Pharmacy and Live Well MD.

Douglas Bowes will serve as Director of Brand Development for Rising Biosciences. Bowes is a successful entrepreneur with over 35 years and the principal owner of a state of the art sterile and non-sterile compounding pharmacy.

Richard Vallette will serve as Director of Pharmacology for the company. He is a certified Pharmacy Regulatory Specialist with certifications in Specialty Pharmaceutical Compounding Techniques and He currently owns and operates a consulting business that provides regulatory and compliance strategies outlining the proper handling of pharmaceuticals to professionals in various medical fields.

CEO Weber is thrilled with the recent appointments, "We are pleased to have assembled our core team of execs and researchers and anticipate explosive growth in the sector given the current industry climate and prospects therein. The business is now prepared to move forward with products we have been working on the first being a non-opioid topical pain cream and the second being a peptide based serum for post melanoma scar reduction although not cannabis based products they will be marketable worldwide."

We also are pleased to announce the Ohio location has begun renovation and we anticipate completion this quarter.

$RSII on Twitter for LIVE company updates!

Forward-Looking Statements: Certain statements in this news release may contain forward-looking information within the meaning of Rule 175 under the Securities Act of 1933 and Rule 3b-6 under the Securities Exchange Act of 1934, and are subject to the safe harbor created by those rules. All statements, other than statements of fact, included in this release, including, without limitation, statements regarding potential future plans and objectives of the company, are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Technical complications, which may arise, could prevent the prompt implementation of any strategically significant plan(s) outlined above. The Company undertakes no duty to revise or update any forward- looking statements to reflect events or circumstances after the date of this release.

Investor Relations

Copyright © 2017 Marketwired. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

While I try To Be The Best @ Anything I Attempt In Life and find the facts to either Support/Deny, I am Neither a Financial Adviser,Investment Adviser,Affiliated with Nobody,Nothing,Nada. These are My Own Personal Opinions And DD I Discover along The way.
Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (4) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
Current Price
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist